(Q37849913)

24 August 2017

title

Chlamydia vaccines: recent developments and the role of adjuvants in future formulations (English)

1 reference

24 August 2017

0 references

Joseph U Igietseme

1

1 reference

24 August 2017

Francis O Eko

series ordinal

2

1 reference

24 August 2017

Carolyn M Black

series ordinal

3

1 reference

24 August 2017

language of work or name

1 reference

1 November 2011

1 reference

Expert Review of Vaccines

24 August 2017

published in

1 reference

24 August 2017

volume

10

1 reference

24 August 2017

issue

11

1 reference

24 August 2017

page(s)

1585-1596

1 reference

High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein gene (omp1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

NAATs to diagnose Chlamydia trachomatis genital infection: a promise still unfulfilled

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Does clinical diagnosis indicate ocular chlamydial infection in areas with a low prevalence of trachoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Effect of Treatment Regimens forNeisseria gonorrhoeaeon Simultaneous Infection withChlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of Chlamydia trachomatis serovar l2 proctitis in The Netherlands among men who have sex with men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Contribution of sexually transmitted infections to the sexual transmission of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Effect of Chlamydia trachomatis coinfection on HIV shedding in genital tract secretions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Treatment of cervicitis is associated with decreased cervical shedding of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Immunological's host profile for HPV and Chlamydia trachomatis, a cervical cancer cofactor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Clinical manifestations of Chlamydia pneumoniae infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Chlamydia and Chlamydiales: more than meets the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

The arrested immunity hypothesis and the epidemiology of chlamydia control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Electron microscopic evidence of persistent chlamydial infection following treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Chlamydial treatment failures: a persistent problem?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Persistence of chlamydial infection after treatment for neonatal conjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

OmpA genotypic evidence for persistent ocular Chlamydia trachomatis infection in Tanzanian village women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Pooling of Chlamydia laboratory tests to determine the prevalence of ocular Chlamydia trachomatis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Chlamydial genovar distribution after community wide antibiotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Should trachoma be treated with antibiotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Pathogenesis of Chlamydia induced pelvic inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Mass treatment with azithromycin for trachoma control: participation clusters in households

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Chlamydia vaccine candidates and tools for chlamydial antigen discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Vaccination against chlamydial infections of man and animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Use of a live chlamydial vaccine to prevent ovine enzootic abortion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

The effect of trachoma virus vaccine on the course of experimental trachoma infection in blind human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Trachoma vaccine field trials in The Gambia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Towards a Chlamydia trachomatis vaccine: how close are we?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Chlamydia trachomatis infection: host immune responses and potential vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Vaccines for Chlamydia infections of the female genital tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Chlamydial genomics and vaccine antigen discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Chlamydia outer membrane protein discovery using genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

DNA immunization with pgp3 gene of Chlamydia trachomatis inhibits the spread of chlamydial infection from the lower to the upper genital tract in C3H/HeN mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Human antibody responses to a Chlamydia-secreted protease factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Chlamydia trachomatis cytotoxicity associated with complete and partial cytotoxin genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Interaction between components of the type III secretion system of Chlamydiaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Antigenic profiling of a Chlamydia trachomatis gene-expression library

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Immunity to murine chlamydial genital infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

T cell responses to Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Chlamydia vaccines: strategies and status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Delivery of Chlamydia vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

A vault nanoparticle vaccine induces protective mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Antigen presentation using novel particulate organelles from halophilic archaea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Contemporary approaches to designing and evaluating vaccines against Chlamydia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Advances in vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Antigen delivery systems and immunostimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Recent advances and novel strategies in vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Vaccine candidates in STD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Trends in vaccine adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

MF59 adjuvant: the best insurance against influenza strain diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Virus-like particles: innate immune stimulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Influenza virosomes as a vaccine adjuvant and carrier system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

CpG DNA as a vaccine adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Chlamydia infections and heart disease linked through antigenic mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Carbohydrate-based immune adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

The cellular paradigm of chlamydial pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

T cell responses in the absence of IFN-gamma exacerbate uterine infection with Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

IL-17A-producing neutrophil-regulatory Tn lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Chlamydia trachomatis strains and virulence: rethinking links to infection prevalence and disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Molecular mimicry and horror autotoxicus: do chlamydial infections elicit autoimmunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

Endogenous processing and presentation of T-cell epitopes from Chlamydia trachomatis with relevance in HLA-B27-associated reactive arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

21 January 2018

Lymphogranuloma venereum

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.139

21 January 2018

Identifiers

DOI

10.1586/ERV.11.139

1 reference

24 August 2017

1 reference